Comparative Pharmacology
Head-to-head clinical analysis: PENLAC versus SANSAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENLAC versus SANSAC.
PENLAC vs SANSAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox, a hydroxypyridone antifungal, inhibits the uptake of essential elements and disrupts fungal cell membrane integrity by chelating polyvalent cations (Fe3+, Al3+). It also inhibits fungal enzymes involved in energy production and detoxification processes.
SANSAC is a synthetic peptide that acts as a selective antagonist of the vasopressin V2 receptor, thereby inhibiting water reabsorption in the renal collecting ducts and promoting aquaresis.
Apply a thin layer to affected nails once daily, preferably at bedtime or 8 hours before washing. Use the provided applicator to apply to the entire nail plate and under the nail tip. Treatment duration is up to 48 weeks.
For adult patients, the recommended dose of SANSAC is 500 mg administered orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 17–21 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe renal failure)
The terminal elimination half-life is approximately 12-15 hours in healthy adults, with clinical significance for once-daily dosing. In patients with renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 24-36 hours, requiring dose adjustment.
Primarily excreted renally as unchanged drug; approximately 90% of absorbed dose recovered in urine within 24 hours; minimal biliary/fecal elimination (<5%)
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug, with an additional 10-15% as metabolites. Fecal elimination constitutes 10-15% mainly via biliary secretion. Less than 5% is eliminated via other routes.
Category C
Category C
Topical Antifungal
Topical Antifungal